Heron Therapeutics, Inc. announced on April 28, 2025, the appointment of Mark Hensley as its new Chief Operating Officer. Mr. Hensley brings over fifteen years of experience in various sales and operations leadership roles within the pharmaceutical industry.
Prior to joining Heron, Mr. Hensley served as Chief Executive Officer of Veloxis Pharmaceuticals, Inc. from 2021 to 2024, and held positions as Chief Operating Officer and Chief Commercial Officer at Veloxis from 2018 to 2021. His career also includes roles of increasing responsibility at Cornerstone Therapeutics and Chiesi USA.
CEO Craig Collard stated that Mr. Hensley's extensive operational and leadership experience positions him to play a pivotal role in Heron's next phase of growth. His expertise is expected to be instrumental in ensuring efficient, effective, and compliant operations as the company advances its strategic priorities and executes growth initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.